Loading…
Perspective for Prophylaxis and Treatment of Cervical Cancer: An Immunological Approach
As the second most common cause of cancer-related death in women, human papilloma virus (HPV) vaccines have been a major step in decreasing the morbidity and mortality associated with cervical cancer. An estimated 490,000 women are diagnosed with cervical cancer each year. Increasing knowledge of th...
Saved in:
| Published in: | International Reviews of Immunology 2012-02, Vol.31 (1), p.3-21 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c518t-9c562ee64606fc550d4cd70315c7dc2436e69434a70f4f0314254ad0d4ef14693 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c518t-9c562ee64606fc550d4cd70315c7dc2436e69434a70f4f0314254ad0d4ef14693 |
| container_end_page | 21 |
| container_issue | 1 |
| container_start_page | 3 |
| container_title | International Reviews of Immunology |
| container_volume | 31 |
| creator | Jenkins, Marjorie Chiriva-Internati, Maurizio Mirandola, Leonardo Tonroy, Catherine Tedjarati, Sean S. Davis, Nicole D'Cunha, Nicholas Tijani, Lukman Hardwick, Fred Nguyen, Diane Kast, W. Martin Cobos, Everardo |
| description | As the second most common cause of cancer-related death in women, human papilloma virus (HPV) vaccines have been a major step in decreasing the morbidity and mortality associated with cervical cancer. An estimated 490,000 women are diagnosed with cervical cancer each year. Increasing knowledge of the HPV role in the etiology of cervical cancer has led to the development and introduction of HPV-based vaccines for active immunotherapy of cervical cancer. Immunotherapies directed at preventing HPV-persistent infections. These vaccines are already accessible for prophylaxis and in the near future, they will be available for the treatment of preexisting HPV-related neoplastic lesions. |
| doi_str_mv | 10.3109/08830185.2011.637254 |
| format | article |
| fullrecord | <record><control><sourceid>informahealthcare_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4164215</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_3109_08830185_2011_637254</sourcerecordid><originalsourceid>FETCH-LOGICAL-c518t-9c562ee64606fc550d4cd70315c7dc2436e69434a70f4f0314254ad0d4ef14693</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EglL4A4T8Ayl2_EjDAlRVPCoh0UURS8s4NglK4miSFvr3OJRWsOlqpJl778wchC4oGTFK0isyHjNCx2IUE0pHkiWx4AdoQFOWRJxJfogGvSTqNSfotG0_CKFMpPwYncRxLCghYoBe5xbaxpquWFnsPOA5-CZfl_qraLGuM7wAq7vK1h32Dk8trAqjSzzVtbFwjSc1nlXVsvalf_8ZTJoGvDb5GTpyumzt-W8dopf7u8X0MXp6fphNJ0-REXTcRakRMrZWckmkM0KQjJssIYwKk2QmDn9YmXLGdUIcd6HPw5c6CzLrKJcpG6KbTW6zfKtsZsKhoEvVQFFpWCuvC_V_Uhe5evcrxankMRUhgG8CDPi2Bet2XkpUD1ptQasetNqADrbLv3t3pi3ZILjdCIo6YK30p4cyU51elx4cBHxF28fvXXHzLyG3uuxyo8GqD7-EOmDdf-M3TNmhTw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Perspective for Prophylaxis and Treatment of Cervical Cancer: An Immunological Approach</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Jenkins, Marjorie ; Chiriva-Internati, Maurizio ; Mirandola, Leonardo ; Tonroy, Catherine ; Tedjarati, Sean S. ; Davis, Nicole ; D'Cunha, Nicholas ; Tijani, Lukman ; Hardwick, Fred ; Nguyen, Diane ; Kast, W. Martin ; Cobos, Everardo</creator><creatorcontrib>Jenkins, Marjorie ; Chiriva-Internati, Maurizio ; Mirandola, Leonardo ; Tonroy, Catherine ; Tedjarati, Sean S. ; Davis, Nicole ; D'Cunha, Nicholas ; Tijani, Lukman ; Hardwick, Fred ; Nguyen, Diane ; Kast, W. Martin ; Cobos, Everardo</creatorcontrib><description>As the second most common cause of cancer-related death in women, human papilloma virus (HPV) vaccines have been a major step in decreasing the morbidity and mortality associated with cervical cancer. An estimated 490,000 women are diagnosed with cervical cancer each year. Increasing knowledge of the HPV role in the etiology of cervical cancer has led to the development and introduction of HPV-based vaccines for active immunotherapy of cervical cancer. Immunotherapies directed at preventing HPV-persistent infections. These vaccines are already accessible for prophylaxis and in the near future, they will be available for the treatment of preexisting HPV-related neoplastic lesions.</description><identifier>ISSN: 0883-0185</identifier><identifier>EISSN: 1937-4364</identifier><identifier>EISSN: 1563-5244</identifier><identifier>DOI: 10.3109/08830185.2011.637254</identifier><identifier>PMID: 22251005</identifier><language>eng</language><publisher>England: Informa Healthcare</publisher><subject>Alphapapillomavirus - immunology ; Animals ; cancer vaccines ; Carcinoma - prevention & control ; Carcinoma - therapy ; Cell Transformation, Neoplastic ; Cell Transformation, Viral ; Female ; gynecologic oncology ; HPV ; Humans ; immunotherapy ; Immunotherapy, Active ; Papillomavirus Infections - prevention & control ; Papillomavirus Vaccines - therapeutic use ; Sexually Transmitted Diseases, Viral - complications ; Sexually Transmitted Diseases, Viral - prevention & control ; Sexually Transmitted Diseases, Viral - virology ; tumor prevention ; Uterine Cervical Neoplasms - prevention & control ; Uterine Cervical Neoplasms - therapy</subject><ispartof>International Reviews of Immunology, 2012-02, Vol.31 (1), p.3-21</ispartof><rights>2012 Informa Healthcare USA, Inc. 2012</rights><rights>Copyright © Informa Healthcare USA, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c518t-9c562ee64606fc550d4cd70315c7dc2436e69434a70f4f0314254ad0d4ef14693</citedby><cites>FETCH-LOGICAL-c518t-9c562ee64606fc550d4cd70315c7dc2436e69434a70f4f0314254ad0d4ef14693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22251005$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jenkins, Marjorie</creatorcontrib><creatorcontrib>Chiriva-Internati, Maurizio</creatorcontrib><creatorcontrib>Mirandola, Leonardo</creatorcontrib><creatorcontrib>Tonroy, Catherine</creatorcontrib><creatorcontrib>Tedjarati, Sean S.</creatorcontrib><creatorcontrib>Davis, Nicole</creatorcontrib><creatorcontrib>D'Cunha, Nicholas</creatorcontrib><creatorcontrib>Tijani, Lukman</creatorcontrib><creatorcontrib>Hardwick, Fred</creatorcontrib><creatorcontrib>Nguyen, Diane</creatorcontrib><creatorcontrib>Kast, W. Martin</creatorcontrib><creatorcontrib>Cobos, Everardo</creatorcontrib><title>Perspective for Prophylaxis and Treatment of Cervical Cancer: An Immunological Approach</title><title>International Reviews of Immunology</title><addtitle>Int Rev Immunol</addtitle><description>As the second most common cause of cancer-related death in women, human papilloma virus (HPV) vaccines have been a major step in decreasing the morbidity and mortality associated with cervical cancer. An estimated 490,000 women are diagnosed with cervical cancer each year. Increasing knowledge of the HPV role in the etiology of cervical cancer has led to the development and introduction of HPV-based vaccines for active immunotherapy of cervical cancer. Immunotherapies directed at preventing HPV-persistent infections. These vaccines are already accessible for prophylaxis and in the near future, they will be available for the treatment of preexisting HPV-related neoplastic lesions.</description><subject>Alphapapillomavirus - immunology</subject><subject>Animals</subject><subject>cancer vaccines</subject><subject>Carcinoma - prevention & control</subject><subject>Carcinoma - therapy</subject><subject>Cell Transformation, Neoplastic</subject><subject>Cell Transformation, Viral</subject><subject>Female</subject><subject>gynecologic oncology</subject><subject>HPV</subject><subject>Humans</subject><subject>immunotherapy</subject><subject>Immunotherapy, Active</subject><subject>Papillomavirus Infections - prevention & control</subject><subject>Papillomavirus Vaccines - therapeutic use</subject><subject>Sexually Transmitted Diseases, Viral - complications</subject><subject>Sexually Transmitted Diseases, Viral - prevention & control</subject><subject>Sexually Transmitted Diseases, Viral - virology</subject><subject>tumor prevention</subject><subject>Uterine Cervical Neoplasms - prevention & control</subject><subject>Uterine Cervical Neoplasms - therapy</subject><issn>0883-0185</issn><issn>1937-4364</issn><issn>1563-5244</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOwzAQRS0EglL4A4T8Ayl2_EjDAlRVPCoh0UURS8s4NglK4miSFvr3OJRWsOlqpJl778wchC4oGTFK0isyHjNCx2IUE0pHkiWx4AdoQFOWRJxJfogGvSTqNSfotG0_CKFMpPwYncRxLCghYoBe5xbaxpquWFnsPOA5-CZfl_qraLGuM7wAq7vK1h32Dk8trAqjSzzVtbFwjSc1nlXVsvalf_8ZTJoGvDb5GTpyumzt-W8dopf7u8X0MXp6fphNJ0-REXTcRakRMrZWckmkM0KQjJssIYwKk2QmDn9YmXLGdUIcd6HPw5c6CzLrKJcpG6KbTW6zfKtsZsKhoEvVQFFpWCuvC_V_Uhe5evcrxankMRUhgG8CDPi2Bet2XkpUD1ptQasetNqADrbLv3t3pi3ZILjdCIo6YK30p4cyU51elx4cBHxF28fvXXHzLyG3uuxyo8GqD7-EOmDdf-M3TNmhTw</recordid><startdate>20120201</startdate><enddate>20120201</enddate><creator>Jenkins, Marjorie</creator><creator>Chiriva-Internati, Maurizio</creator><creator>Mirandola, Leonardo</creator><creator>Tonroy, Catherine</creator><creator>Tedjarati, Sean S.</creator><creator>Davis, Nicole</creator><creator>D'Cunha, Nicholas</creator><creator>Tijani, Lukman</creator><creator>Hardwick, Fred</creator><creator>Nguyen, Diane</creator><creator>Kast, W. Martin</creator><creator>Cobos, Everardo</creator><general>Informa Healthcare</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20120201</creationdate><title>Perspective for Prophylaxis and Treatment of Cervical Cancer: An Immunological Approach</title><author>Jenkins, Marjorie ; Chiriva-Internati, Maurizio ; Mirandola, Leonardo ; Tonroy, Catherine ; Tedjarati, Sean S. ; Davis, Nicole ; D'Cunha, Nicholas ; Tijani, Lukman ; Hardwick, Fred ; Nguyen, Diane ; Kast, W. Martin ; Cobos, Everardo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c518t-9c562ee64606fc550d4cd70315c7dc2436e69434a70f4f0314254ad0d4ef14693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Alphapapillomavirus - immunology</topic><topic>Animals</topic><topic>cancer vaccines</topic><topic>Carcinoma - prevention & control</topic><topic>Carcinoma - therapy</topic><topic>Cell Transformation, Neoplastic</topic><topic>Cell Transformation, Viral</topic><topic>Female</topic><topic>gynecologic oncology</topic><topic>HPV</topic><topic>Humans</topic><topic>immunotherapy</topic><topic>Immunotherapy, Active</topic><topic>Papillomavirus Infections - prevention & control</topic><topic>Papillomavirus Vaccines - therapeutic use</topic><topic>Sexually Transmitted Diseases, Viral - complications</topic><topic>Sexually Transmitted Diseases, Viral - prevention & control</topic><topic>Sexually Transmitted Diseases, Viral - virology</topic><topic>tumor prevention</topic><topic>Uterine Cervical Neoplasms - prevention & control</topic><topic>Uterine Cervical Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jenkins, Marjorie</creatorcontrib><creatorcontrib>Chiriva-Internati, Maurizio</creatorcontrib><creatorcontrib>Mirandola, Leonardo</creatorcontrib><creatorcontrib>Tonroy, Catherine</creatorcontrib><creatorcontrib>Tedjarati, Sean S.</creatorcontrib><creatorcontrib>Davis, Nicole</creatorcontrib><creatorcontrib>D'Cunha, Nicholas</creatorcontrib><creatorcontrib>Tijani, Lukman</creatorcontrib><creatorcontrib>Hardwick, Fred</creatorcontrib><creatorcontrib>Nguyen, Diane</creatorcontrib><creatorcontrib>Kast, W. Martin</creatorcontrib><creatorcontrib>Cobos, Everardo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International Reviews of Immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jenkins, Marjorie</au><au>Chiriva-Internati, Maurizio</au><au>Mirandola, Leonardo</au><au>Tonroy, Catherine</au><au>Tedjarati, Sean S.</au><au>Davis, Nicole</au><au>D'Cunha, Nicholas</au><au>Tijani, Lukman</au><au>Hardwick, Fred</au><au>Nguyen, Diane</au><au>Kast, W. Martin</au><au>Cobos, Everardo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Perspective for Prophylaxis and Treatment of Cervical Cancer: An Immunological Approach</atitle><jtitle>International Reviews of Immunology</jtitle><addtitle>Int Rev Immunol</addtitle><date>2012-02-01</date><risdate>2012</risdate><volume>31</volume><issue>1</issue><spage>3</spage><epage>21</epage><pages>3-21</pages><issn>0883-0185</issn><eissn>1937-4364</eissn><eissn>1563-5244</eissn><abstract>As the second most common cause of cancer-related death in women, human papilloma virus (HPV) vaccines have been a major step in decreasing the morbidity and mortality associated with cervical cancer. An estimated 490,000 women are diagnosed with cervical cancer each year. Increasing knowledge of the HPV role in the etiology of cervical cancer has led to the development and introduction of HPV-based vaccines for active immunotherapy of cervical cancer. Immunotherapies directed at preventing HPV-persistent infections. These vaccines are already accessible for prophylaxis and in the near future, they will be available for the treatment of preexisting HPV-related neoplastic lesions.</abstract><cop>England</cop><pub>Informa Healthcare</pub><pmid>22251005</pmid><doi>10.3109/08830185.2011.637254</doi><tpages>19</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0883-0185 |
| ispartof | International Reviews of Immunology, 2012-02, Vol.31 (1), p.3-21 |
| issn | 0883-0185 1937-4364 1563-5244 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4164215 |
| source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
| subjects | Alphapapillomavirus - immunology Animals cancer vaccines Carcinoma - prevention & control Carcinoma - therapy Cell Transformation, Neoplastic Cell Transformation, Viral Female gynecologic oncology HPV Humans immunotherapy Immunotherapy, Active Papillomavirus Infections - prevention & control Papillomavirus Vaccines - therapeutic use Sexually Transmitted Diseases, Viral - complications Sexually Transmitted Diseases, Viral - prevention & control Sexually Transmitted Diseases, Viral - virology tumor prevention Uterine Cervical Neoplasms - prevention & control Uterine Cervical Neoplasms - therapy |
| title | Perspective for Prophylaxis and Treatment of Cervical Cancer: An Immunological Approach |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A30%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-informahealthcare_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Perspective%20for%20Prophylaxis%20and%20Treatment%20of%20Cervical%20Cancer:%20An%20Immunological%20Approach&rft.jtitle=International%20Reviews%20of%20Immunology&rft.au=Jenkins,%20Marjorie&rft.date=2012-02-01&rft.volume=31&rft.issue=1&rft.spage=3&rft.epage=21&rft.pages=3-21&rft.issn=0883-0185&rft.eissn=1937-4364&rft_id=info:doi/10.3109/08830185.2011.637254&rft_dat=%3Cinformahealthcare_pubme%3E10_3109_08830185_2011_637254%3C/informahealthcare_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c518t-9c562ee64606fc550d4cd70315c7dc2436e69434a70f4f0314254ad0d4ef14693%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/22251005&rfr_iscdi=true |